Thor Halfdanarson, Vice President of the North American Neuroendocrine Tumor Society, shared on X:
“A reminder that NETs are radiosensitive tumors. Locally advanced, nonmetastatic, unresectable (extensive vascular involvement, cavernous portal vein transformation) G2 panc NET (Ki67 9%). CAPTEM x12 with good partial response, followed by CRT with capecitabine. 23 months post CRT.”
More posts featuring Thor Halfdanarson.